Ranibizumab for Diabetic Traction Retinal Detachment

The Effect of Intravitreous Ranibizumab on Intra-Operative Bleeding During Pars Plana Vitrectomy for Diabetic Traction Retinal Detachment

The purpose of this study was to assess the effect of ranibizumab in reducing intraoperative vitreous haemorrhage during pars plana vitrectomy, thus facilitating surgery and improving its anatomical and functional results in patients with advanced proliferative diabetic retinopathy and traction retinal detachment.

Inclusion Criteria:

• Macular traction retinal detachment lasting three months or less secondary to diabetic retinopathy.

Exclusion Criteria:

• Massive vitreous hemorrhage preventing from detailed posterior pole examination;
• Previous intra-ocular surgery other than cataract surgery
• Hemodialysis, known bleeding disorders or use of anticoagulants drugs other than aspirin
• Prothrombin time, partial thromboplastin time or platelet count without normal limits
• History of previous thromboembolic events